We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Interest in MicroRNA Research Driving Growth in Related Market Tools

By LabMedica International staff writers
Posted on 01 Jun 2012
Print article
A new study shows that an increased number of pharmaceutical and biotech companies are becoming interested in microRNA (miRNA) research due to advancements in molecular diagnostics and therapeutics. As a result, a larger number of distribution companies are offering miRNA research tools and expanding the spectrum of their applications to cater to a wider range of life science areas.

In a recent study titled Analysis of MicroRNA Tools and Services Market in Europe, Frost & Sullivan (Palo Alto, CA, USA; www.frost.com), a global research and analysis company, examined various miRNA tools and services, including expression profiling and phenotypic screening, to determine that miRNA research is expanding across different fields.

The analysis found that miRNA research has become increasingly prominent in the cardiovascular, virology, endocrinology, plant science, and genetic disease fields. This has caused several other fields to develop an interest in auditing their gene expression analyses or epigenetic research by profiling miRNAs, explained Vinodh Jyotikumar, research consultant, Frost & Sullivan.

As new miRNAs and their functions are discovered, additional research fields may adopt an interest in the role of miRNAs in their disciplines, leading to the need for a wider variety of research tools.

A surge in miRNA research over the past four years has already led several life sciences vendors to offer miRNA research instruments. As competition intensifies, market participants will need to expand and differentiate their product options and capabilities to accommodate a broader range of interested fields.

"Service providers that do not offer in-house technologies must differentiate themselves by expanding tool options or adding capabilities," added Mr. Jyotikumar. "Companies may opt to provide multiple microarrays from various vendors, develop their own tools or offer specialized products, such as multiplex panels aimed at specific diseases."

Analysis of MicroRNA Tools and Services Market in Europe is part of the Frost & Sullivan Clinical Diagnostics Growth Partnership Services program.


Related Links:
Frost & Sullivan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.